TY - JOUR T1 - Impact of pneumothorax as complication of endobronchial valve treatment on patient-reported outcomes JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3798 VL - 58 IS - suppl 65 SP - PA3798 AU - Marlies van Dijk AU - Jorine Hartman AU - Karin Klooster AU - David Koster AU - Dirk-Jan Slebos Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3798.abstract N2 - Introduction: Pneumothorax is a common, well treatable complication of endobronchial valve (EBV) treatment.Aims: We aimed to investigate whether a pneumothorax after EBV-treatment affects patient reported outcomes (PRO’s).Methods: We included patients treated with EBV’s in our hospital between September 2016 and December 2019 with available 1-year follow up data including the Patient Specific Complaints questionnaire (PSC), for which patients rate their impairment on three self-chosen activities on a scale from 0 to 10.Results: 136 patients (64% female, age 63±7years, FEV1 28±8%pred, RV 233±41%pred) were included, 16 of these patients (12%) had a pneumothorax. No significant differences in the PSC and clinical outcomes between groups at one-year follow up were found (table 1). In both groups PSC, six-minute walk distance and lung function improved significantly compared to baseline (all p<0.05).Conclusion: In this retrospective analysis, patients who developed a pneumothorax after EBV-treatment reported an improvement in patient reported outcomes comparable to patients who did not develop a pneumothorax after EBV-treatment. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3798.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -